Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

A 22-year-old male experienced significant hair regrowth and stopped shedding after using dutasteride and spironolactone for 3-4 months. Spironolactone is discussed as an antiandrogen, typically used for women or transitioning individuals, and not commonly recommended for men due to potential side effects.

The user experienced significant hair regrowth after switching from finasteride to dutasteride and from topical to oral minoxidil, despite some patchiness along the hairline. The user reduced the oral minoxidil dose due to low blood pressure concerns.

Using finasteride and minoxidil for six months led to improved hair density and appearance. A temporary decrease in libido was noted as a side effect.

The user changed their hair loss treatment to 5mg oral Minoxidil and 2.5mg Dutasteride daily, resulting in significant hair regrowth over two months. They also used Nizoral 2% Ketoconazole shampoo to improve scalp health.

A 22-year-old trans woman has been on 6mg estradiol enanthate for five months. She reports thicker and healthier hair but not much regrowth yet.

Switching from finasteride to dutasteride for hair loss treatment. Dutasteride is suggested as a more effective alternative.

The user is taking 1mg finasteride daily and RU58841 5% but still experiencing hair loss. They are considering adding topical finasteride or switching to dutasteride, and are not planning to use minoxidil until hair loss stabilizes.

Trans woman experiences hair thinning despite low testosterone and treatments like finasteride and microneedling. Possible causes discussed include past eating disorder and current stack of medications and supplements.

User switched from finasteride to combination dutasteride and finasteride for hair density improvement. They noticed less hair shedding and more youthful skin, with a reply suggesting less DHT could increase elastin in skin.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The conversation discusses hair regrowth and miniaturization, with the user transitioning to oral dutasteride and oral minoxidil, and occasionally using topical minoxidil. The user observes baby hairs near the hairline but less on the scalp, indicating possible regrowth and shedding.

A 36-year-old male has been using 1 mg finasteride for 2 years and recently switched to dutasteride for 3.5 months, noticing stable hair with slight thickening and no significant side effects. Other users discuss their experiences with finasteride, minoxidil, and dutasteride, with some reporting no results or side effects.

A 32-year-old man is using oral finasteride, oral minoxidil, and ketoconazole shampoo to combat hair loss, with plans to add dermastamping and possibly switch to dutasteride. He is seeing progress and remains hopeful despite mixed opinions from others about the effectiveness of his treatment.

The user noticed some hair growth after two months of using finasteride. Others advised patience, noting that significant results take longer.

The conversation discusses the potential risks of introducing anabolic steroids, specifically trenbolone, during an active hair shedding phase caused by RU58841, while on TRT and low-dose finasteride. Users advise waiting for hair shedding to stabilize before adding new compounds, highlighting the potential for increased hair loss and health risks.

The user has been using 2.5mg oral minoxidil and 1mg finasteride daily for 2.5 months, noticing increased hair density and new hair growth. There is concern about elevated estradiol levels, possibly due to finasteride, but no significant side effects have been reported yet.

The user started with Finasteride at 19, added Dutasteride and Minoxidil at 26, but continues to experience hair loss. Suggestions include checking health markers, considering genetics, and possibly increasing Minoxidil dosage.

The user is experiencing progress in hair regrowth using 1 mg finasteride and 5 mg minoxidil, with no side effects reported. There is a discussion about whether to switch from finasteride to dutasteride, but many advise against it since finasteride is showing good results.

The user is considering increasing their dutasteride dose and trying clascoterone or RU58841 for hair loss stabilization. They have used finasteride, minoxidil, and dutasteride, with some success but recent setbacks.

OP plans to switch from topical to oral minoxidil due to limited results and is advised to overlap both for a few weeks before discontinuing the topical. Oral minoxidil may be more effective for non-responders to topical treatment.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

Switching from finasteride to dutasteride led to hairline regression and scalp issues for some users, prompting a return to finasteride. Users reported better maintenance and regrowth with finasteride compared to dutasteride, despite using oral minoxidil throughout.

Hair loss treatments include topical and oral minoxidil, low-level laser light therapy, and peptide serums. Bryan Johnson avoids finasteride and dutasteride due to potential side effects, focusing instead on his own protocol with these treatments.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

The user experienced significant hair growth and density improvement over nine months using 1 mg finasteride daily, initially 5% topical minoxidil, then transitioning to 2.5 mg and later 5 mg oral minoxidil, along with weekly microneedling. Noticeable changes were observed after three months, with the most significant progress by month nine.

The conversation humorously discusses hair loss treatments, focusing on finasteride, dutasteride, and minoxidil, with users joking about misleading others to keep treatments secret. It includes sarcastic comments about side effects and ineffective remedies.

A trans man experiencing hair loss after starting testosterone treatment has seen positive results using topical minoxidil and finasteride, though his hair remains thin. He is considering continuing his current treatment and exploring additional options like microneedling and Breezula, while acknowledging the impact of testosterone on hair loss.

The user is considering switching from Finasteride to Dutasteride for better hair regrowth, despite concerns about potential shedding and side effects. Opinions vary, with some suggesting the switch for stronger results and others advising caution due to possible side effects and the importance of consulting a doctor.

A person in prison is seeking advice on maintaining hair with treatments like Minoxidil and dutasteride, and others suggest options like Propecia, HRT, or going bald. The conversation includes jokes and serious concerns about the challenges of accessing hair loss treatments in prison.